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Summary: One hundred and seventy five subjects with chronic liver diseases which included patients with 
chronic active hepatitis (90), liver cirrhosis (31) and asymptomatic hepatitis B carriers (54), were included in 
the study. Hepatitis B virus (HBV) specific DNA-polymerase activity and HBe-markers were tested as 
markers of HBV-multiplicaiton. In HBsAg positive samples, DNA-P activity was positive in 44.4% of the 
HBV carriers, 52.9% of the patients with chronic active hepatitis and 81.8% of the patients with liver cirrho- 
sis. The corresponding fi ures for the presence of HBeAg in these groups were 18.5, 26.5 and 45.5% respec- 
tively. Virus multiplication was also observed in 41.1 and 44.4% patients with chronic active hepatitis and 
liver cirrhosis respectively, in the absence of HBsAg. The results of the present study show that hepatitis B
virus is the most important etiological factor of chronic liver diseases in India. Most of our patients of chronic 
liver diseases seems to have contacted HBV infection as young adults and the mode of transmission is likely 
to be horizontal rather than vertical. The virus replicating markers correlate well with the severity of the liver 
injury and decreased with the age. DNA-P activity is a more sensitive marker of viral multiplication than 
HBeAg. Viral multiplication was also found to occur in the absence of the usual HBV markers. Continued 
viral multiplication i patients with chronic active hepatitis and liver cirrhosis is implicated in continued liver 
injury and progressive liver disease. Gastroenterol Jpn 1990;25:258-264 
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Introduction 
Studies of hepatitis B virus infections have shown 
a close relationship between the phase of active 
viral replication and the development of hepatic 
lesions 1-3. During active viral replications, liver 
cell necrosis was assumed to occur as a result of 
the direct cytopathic effect of HBV on hepato- 
cytes 4'5. However, recent studies indicated the 
role of the immune system in the pathogenesis of
liver diseases associated with HBV infection 6'7. 
Active viral replication has been associated with 
the presence of hepatitis B antigen (HBeAg) and 
the underlying active liver disease and its rela- 
tionship with the presence of hepatitis B virus 
(HBV) DNA in serum is well documented 8'9. De- 
tection of HBV-DNA and/or DNA-polymerase 
in serum is a specific and sensitive method for the 
determination of intact HBV in serum and the 
degree of HBV replication 8'~~ which is inde- 
pendent of HBeAg/anti-HBe system 13-~5. The 
presence of HBV-associated DNA-polymerase 
(DNA-P) is direct evidence of the presence of 
DNA containing HBV 16'~7 and an indication of 
HBV infection. 
The present study was carried out to find out 
the status of HBV replication in HBsAg-positive 
and HBsAg-negative (also IgM anti-HAV-neg- 
ative) patients with chronic active hepatitis 
(CAH), cirrhosis of the liver (CL) and asympto- 
matic HBV carriers. Comparative values of 
DNA-P activity and HBe-markers were also as- 
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Table 1 HBV-markers in different age groups of patients with chronic liver disease 
Age group HBsAg DNA-P HBeAg 
years HC CAH CL HC CAH CL HC CAH CL 
10-20 1 3 3 2 0 2 1 0 2 
21-30 29 9 2 10 5 3 4 3 1 
31-40 10 4 4 5 6 6 2 2 3 
41-50 7 7 7 3 3 4 1 2 3 
51-60 6 6 5 3 2 3 2 1 1 
61-70 1 5 1 1 2 0 0 1 0 
Total 54 34 22 24 18 18 10 9 10 
Percentage* 100 38 71 44 20 38 19 10 31 
HC: HBV carriers; CAH: chronic active hepatitis; CL: cirrhosis of liver 
* Values are percentages of the total of patients in each group. 
sessed as markers for viral replication. 
Materials and Methods 
Patients 
Sera from 175 consecutive cases of chronic liver 
disease which included chronic active hepatitis 
(90), liver cirrhosis (31) and asymptomatic hepa- 
titis B carriers (HBV-carriers) (54), and admitted 
to the wards of the Department of Gastroenter- 
ology at the All India Institute of Medical Sci- 
ences, were included in the study. All the samples 
were tested for HBV infection including the 
markers of virus multiplication i order to find out 
the magnitude and role of HBV infection in 
chronic liver diseases. 
The diagnosis was confirmed by standard clini- 
cal, biochemical, serological and histological cri- 
teria 1s'19. Hepatitis B virus carriers were diag- 
nosed from the voluntary blood donors during 
screening of their sera for HBsAg by enzyme 
linked immunosorbent assay (ELISA). In addi- 
tion, 45 sera samples from healthy students from 
the University of Bergen, Norway, were tested as 
a control group. 
Serological investigations 
HBsAg in serum samples was tested by micro- 
ELISA technique 2~ HBeAg and anti-HBe in 
serum samples were assayed by the HBe-EIA 
kits available commercially from the Abbott Lab- 
oratories, North .Chicago, Illinois. DNA-poly- 
merase activity was measured in serum samples 
by a modification of the technique of Fang et a121 . 
Details of the modification are described else- 
where 22. 
Statistics 
The test of proportion was applied to evaluate 
the level of differences in the groups. 
Results 
The mean age of the asymptomatic HBV carriers, 
patients with CAH and the patients with liver cir- 
rhosis (CL) was found to be 33.4+ 12.7 (range 15- 
54), 39.1+ 15.9 (range 9-66) and 41.2 + 13.7 (range 
14-67) years respectively. The corresponding 
male/female ratios in these groups were 2.1:1, 
3.1:1 and 5.7:1 respectively. The patients with 
CAH and CL belonged to a higher age group in 
comparison to asymptomatic HBV-carriers 
(P<0.05). The HBV viral markers in different age 
groups are presented in Table 1. 
All the 45 sera samples from healthy students 
from the University of Bergen, Norway, were 
negative for HBsAg and markers of viral replica- 
tion. Thirty four of 90 patients with CAH and 22 
of 31 patients with CL were positive for HBsAg. 
While estimating the proportion of patients with 
HBV multiplication, the patients with chronic 
liver diseases and those without any markers of 
HBV-infection were excluded form the analysis 
for all practical purposes. All the patients with 
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Table 2 Infection due to hepatitis B virus in patients with chronic 
liver diseases 
Disease Number HBsAg +ve HBsAg -ve Number with 
DNA-P +ve HBV markers 
CAH 90 34 23 57 63.3%) 
CL 31 22 4 26 83.8%) 
Total 121 56 (46.3%)27 (22.3%) 83 68.6%) 
CAH: Chronic active hepatitis, CL: Cirrhosis of the liver 
Table 4 Status of HBe-markers in samples positive for DNA-P 
activity 
Groups DNA-P  HBeAg anti-HBe HBe-markers 
+ve +ve +ve -ve 
HBV-carriers 24 6 (25.0) 7 (29.2) 11 (45.8) 
CAR 18 8 (44.4) 7 (38.9) 3 (16.7) 
Cirr. liver 18 9 (50.0) 3 (16.7) 6 (33.3) 
Total 60 23 (38.4) 17 (28.3) 20 (33.3) 
Values of parenthesis how percent values 
chronic liver diseases are enumerated at Table 2 in 
order to provide a holistic picture of HBV status 
in these patients. In all about 63% of the CAH pa- 
tients and 84% of the cirrhotics had markers of 
HBV infection in their sera either in the form of 
HBeAg and/or DNA-polymerase. The overall 
evidence of HBV infection in patients with 
chronic liver disease was 68.6%. 
The status of viral replication in various groups 
of patients with HBV infection is shown in Table 
3. Among the asymptomatic HBV carriers, 
DNA-P activity was found to be present in 44.4% 
of the subjects in comparison to HBeAg positivity 
in 18.5% of the same subjects. Among the chronic 
active hepatitis patients, positive for HBsAg, 
52.9% showed DNA-P activity while only 26.5% 
were positive for HBeAg. In patients with liver 
cirrhosis, 81.8% of HBsAg positive subjects 
showed DNA-P activity in comparison to the 
presence of HBeAg in 45.5% of the patients. Out 
of a total of 110 samples positive for HBsAg, 
54.5% showed positive DNA-P activity while 
26.4% of these subjects were positive for HBeAg. 
DNA-P activity was found to be present in a 
significantly large number of patients with the liv- 
er cirrhosis in comparison to asymptomatic carri- 
ers (P<0.01) and the CAH group (P<0.05). 
However, the difference between the cirrhotics 
and the asymptomatic HBV carriers in relation to 
the CAH group was not significant. 
Among the serum samples positive for DNA-P 
activity (Table 4), 38.3% were found to be as- 
sociated with the presence of HBeAg, 21.7% 
were associated with anti-HBe, while in the re- 
maining 33.3%, DNA-P activity was present in 
the absence of any of the HBe-markers. 
The present study shows the prevalence of 
HBsAg in over 55% of the patients with chronic 
liver diseases over the age of 40 whereas DNA-P 
activity and HBeAg were found to be present in 
38.9 and 42.1% of these patients respectively 
(Fig. 1). However, there was no significant differ- 
ence in the presence of HBsAg, DNA-P activity 
and HBeAg in asymptomatic HBV carriers be- 
tween patients above and below the age of 40 
(Fig. 2). 
Among the 56 subjects with CAH negative 
for HBsAg, 23 (41.1%) showed the presence of 
Table 3 Status of DNA-P and HBeAg among different groups of HBV infection 
Groups Number HBsAg +ve DNA-P +ve HBeAg +ve 
HBV carriers 54 54/54 (100.0) 24/54 (44.4) 10/54 (18.5) 
CAH 90 34/90 (37.8) 18/34 (52.9) 9/34 (26.5) 
Cirrhosis of liver 31 22/31 (71.0) 18/22 (81.8) bc 10/22 (45.5) a 
Total 175 110/175 (62.9) 50/110 (54.5) 29/110 (26.4) 
Values in parenthesis show per cent values 
a: Difference significant (P<0.05) in comparison to HBV-carriers 
b: Difference significant (P<0.01) in comparison to HBV-carriers 
c: Difference significant (P<0.05) in comparison to CAH group 
April 1990 HB V replication in patients witlz chronic liver diseases 261 
< 40 YEARS 
~ 40 YEARS 
90 
80" 
70 
~j 60" 
50- 
40 
30- 
20- 
}04 
0t 
(n) 
HSsA i DNA-P HbeAg 
(s6) (36) Os) 
CHRONtC LW~R D[Ss 
Fig. 1 The prevalence of viral markers in relation to age in pa- 
tients with chronic liver diseases. Values in parenthesis 
show the number of patients tested for each parameter. 
Shaded columns shows the patients aged less than 40 
while the open columns show patients aged more then 
40. 
DNA-P activity while among HBsAg negative pa- 
tients with cirrhosis of liver DNA-P activity posi- 
tivity was 44.4% (4/9 subjects). 
Discussion 
The mean age of HBV carriers, patients with 
CAH and patients with cirrhosis in the present 
study was 33.4, 39.1 and 41.2% years respec- 
tively. The corresponding evidence of HBV repli- 
cation as tested by DNA-P activity in these pa- 
tients was observed in 44, 53 and 82% of the sub- 
jects respectively. The presence of replicating 
HBV in the liver of the patients age over 40 in- 
dicate that they have contacted the infection in 
their adolescence or as young adults. Vertical 
transmission has been shown not to be a major 
mode of HBV transmission i  India 23. Most of the 
Indian patients eems to contact HBV infection 
by other modes such as the parenteral route or 
prolonged contact, particularly because most of 
the transfusion services in this country do not 
have screening facilities for HBsAg and sanitation 
is a persistent and continuing problem. 
Markers of HBV infection were present in 
about 69% of the patients with chronic liver dis- 
eases, implicating HBV to be the single major 
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Fig. 2 The prevalence of viral markers in relation to the age in 
hepatitis B virus carriers. Values in parenthesis show the 
number of patients tested for each parameter. Shaded 
columns show the patients aged less than 40 while the 
open columns show patients aged more than 40. 
cause. This observation was supported by the fact 
that about 84% of the histologically proved cir- 
rhotics has either HBsAg or DNA-P in their sera 
(Table 2). Even though it was believed that HBV 
was the most important agent inducing chronic 
liver disease in India, it has not been well docu- 
mented, except for one study with very few cases 24 
where HBV was demonstrated to be the sole 
cause of cirrhosis in India. 
In all the three goups i.e. asymptomatic HBV- 
carriers, patients with chronic active hepatitis and 
patients with liver cirrhosis, DNA-P activity was 
present in significantly more of cases compared to 
HBeAg. The presence of HBV-DNA has already 
been shown to be present in the serum at various 
stages of HBV-infection regardless of HBeAg de- 
tection 25'26, and the absence of HBeAg in these 
patients does not necessarily reflect low levels of 
viral particles in the serum or the occurence of 
HBV genome varients. The relative insenstivity 
of radioimmunoasay for HBeAg rather than the 
absence of HBeAg/anti-HBe has been shown to 
reflected by the DNA-P activity 27. The testing of 
the sera for HBeAg/Ab to show infectiousness 
and to decide the prognosis has already been 
questioned 26"28 specifically in CAH and cirrhosis 
of liver 29. The assay of DNA-P has been shown to 
be useful in predicting the chronic sequelae in pa- 
tients with acute viral hepatitis 3~ In asympto- 
matic HBV-carriers, the DNA-P activity was 
found to be present in 44.4% cases, in comparison 
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to 18.5% positivity of HBeAg. Kam et a131 have 
demonstrated significant quantitative and qualita- 
tive differences among the asymptomatic HBV- 
carriers in relation to the presence of hepatitis B 
virus DNA (HBV-DNA) and HBeAg. DNA-P 
activity has also been shown to be present in as 
low as 5.5% of the asymptomatic HBV-carriers 21 . 
The frequency of HBeAg in asymptomatic HBV- 
carriers in various countries has been shown to 
range from 0% to as high as 50% 32,33 and anti- 
HBe between 18.6 to 74% 32 
The finding of evidence of viral replication in 
44.4% of HBV-carriers is of concern, as this may 
lead to chronic liver disease in due course of time. 
HBV-DNA has been found to integrate into hep- 
atocyte DNA in cases of CAH 34'35 and liver cir- 
rhosis 34. The integration of viral sequences and 
persistant surface antigen production contributes 
to the development of progressive liver disease 
and the cirrhosis is observed in clinically asympto- 
matic carriers 36. 
Another important observation of the present 
study was the presence of HBV replication in a 
significantly higher proportion of the patients 
with cirrhosis in comparison to patients with CAH 
and HBV-carriers. Our data confirms the earlier 
findings of increased activity of DNA-P 3~ and 
HBV-DNA 9 even up to 76% in patients with 
CAH and HBV-DNA in 70% of the patients 
which progressed from chronic active hepatitis to 
cirrhosis of liver 37'38. However it is difficult to 
assert from the available data based on detection 
of DNA-P or HBeAg, whether ther cytopathic 
effect of virions or the immune system is involved 
in the mechanism of hepatic necrosis in chronic 
liver diseases. 
Viral replication was also found to be present in 
44.4% of the patients with cirrhosis of liver and 
41.1% of the patients with chronic active hepa- 
titis which were negative for HBeAg. This data 
strengthens the conclusion that HBV multiplica- 
tion is recorded in extremely high proportions in 
patients with chronic active hepatitis and cirrhosis 
of liver. Higher frequency of DNA-P positivity in 
HBsAg negative patients with liver cirrhosis and 
chronic active hepatitis suggest hat multiplica- 
tion of HBV may occur in the absence of con- 
ventional HBV markers. Similar observations 
were made in these groups by Brechot et a134 and 
Nalpas et a139. The explanation given for such an 
event was that HBsAg could be masked by im- 
mune complexes or be present in the serum at 
very low levels. 
The dominance of DNA-P activity in the serum 
over the HBe-markers as a positive marker of 
viral replication has been further emphasized by 
the fact that in DNA-P positive samples, on an 
average, HBeAg positivity was 38.3% and anti- 
HBe in 22.7%. In 33.3% of the DNA-P positive 
samples, both HBeAg and anti-HBe wre absent. 
The percentage being as high as 45.8% in HBV- 
carriers (Table 4). In the group of HBV-DNA 
positive patients, the presence of liver disease has 
been shown to be significantly connected with the 
absence of HBeAg in serum and suggested that 
the HBeAg/anti-HBe status in HBV-DNA posi- 
tive sera distinguish two different ypes or phases 
of chronic type B hepatitis 14. There is an incon- 
sistent relationship between the time of serocon- 
version of HBeAg to anti-HBe and the disappear- 
ance of HBV-DNA 15. In CAH, DNA-P activity 
seems to be a good marker of positive viral repli- 
cation in comparison to HBeAg. The presence of 
DNA-P in the serum of some HBeAg/anti-HBe 
positive carriers (29.2) suggest that they may be 
infective a2'41. The absence of HBe-markers in 
large number of samples may be due to the rela- 
tive insensitivity of the enzyme immunoassay for 
detection of HBeAg/anti-HBe or "e" window pe- 
riod 27. In contrast o earlier reports '26'42, only 
50% of our DNA-P positive patients with cir- 
rhoris of the liver and none with chronic active 
hepatitis, showed the presence of HBeAg. 
Continued viral replication has been shown to be 
present in a significant large number of patients 
after HBeAg seroconversion i Taiwan 37. The 
presence of anti-HBe has been shown to be a 
marker of low viral replication, rather than the 
complete absence of viral replication 9.
The present study reports evidence of virus 
multiplication in a very high proportion in pa- 
tients with liver cirrhosis and chronic active hepa- 
titis. DNA-P activity was found to decrease with 
age. In addition to individual host immune fac- 
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tors 43, inflammatory changes in the liver of chron- 
ic HBV infection patients have been found to be 
associated with high levels of viral production 
maintained for long periods 37'4a'45, leading to pro- 
gressive disease. High viral multiplication of 
HBV virus in these patients also implies the lack 
of viral integration in these groups whcih may be 
due to the shorter duration of the disease process 
or variable infectivity. An unpublished report 
from this center revealed hepatocellular carci- 
noma with cirrhosis in 5 patients in comparison to 
hepatocellular carcinoma with normal liver in 11 
patients as observed by laparoscopy and multiple 
biopsies under direct vision. A low incidence of 
hepatocellular carcinoma associated with cirrho- 
sis in our population might be consistent with the 
present observations. 
Our findings are significant in relation to under- 
standing of pathogenesis with particular need for 
treatment with anti-viral agent to stop or arrest 
the process of replication, in order to prevent the 
liver injury. The carrier state may also be not as 
benign for individuals as considered in the past 
and raises the question of anti-viral therapy in 
them. 
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